Collaborative drug therapy modification (CDTM): Facilitators, barriers, and perceptions of individual pharmacist participation in Georgia

Sharmon P Osae; Russ Palmer; Ashlee Harvey; Chelsea A Keedy; Devin L Lavender; Beth Bryles Phillips; Blake R Johnson; Henry N Young; Rebecca H Stone

doi:10.1016/j.japh.2024.102041

Collaborative drug therapy modification (CDTM): Facilitators, barriers, and perceptions of individual pharmacist participation in Georgia

J Am Pharm Assoc (2003). 2024 Feb 16:102041. doi: 10.1016/j.japh.2024.102041. Online ahead of print.

Authors

Sharmon P Osae, Russ Palmer, Ashlee Harvey, Chelsea A Keedy, Devin L Lavender, Beth Bryles Phillips, Blake R Johnson, Henry N Young, Rebecca H Stone

PMID: 38367860
DOI: 10.1016/j.japh.2024.102041

Abstract

Background: Georgia Board of Pharmacy (BOP) regulations permit pharmacists to engage in collaborative drug therapy modification (CDTM) with physicians, allowing them to perform patient assessments, adjust pharmacotherapy, and order laboratory tests. Pharmacist-led CDTM can positively affect health outcomes leading to reduced healthcare expenditures. CDTM is underutilized, with < 1% of Georgia pharmacists holding an active license to practice CDTM.

Objective(s): The objective of this study was to examine CDTM licensed pharmacists' perceptions of facilitators and barriers in providing CDTM.

Methods: Georgia-licensed CDTM pharmacists were invited to participate in a 60-minute qualitative interview. Interview questions were developed from electronic survey responses. The interview was designed to elicit information regarding perceived benefits and barriers to CDTM implementation. Guided by the Consolidated Framework for Implementation Research, thematic analysis was applied to identify themes using ATLAS.ti software to code. Themes were described qualitatively and prevalence of each was reported.

Results: Nine interviews were conducted, and data saturation was achieved at interview 6. After resolution of discrepancies, 100% coding agreement was reached among 2 independent researchers. Nine themes were identified, and each was categorized as a facilitator or barrier to establishing pharmacist-led CDTM in Georgia. Themes associated with facilitating were (prevalence %) (1) practice autonomy (100), (2) personal attributes (100), (3) having support (100), and (4) institutional logistics (88). Barrier themes included issues concerning (5) the Georgia BOP (100), (6) pharmacist autonomy (88), (7) lack of provider status (88), (8) institutional restrictions (75), and (9) personal development (e.g., confidence) (22).

Conclusion: Facilitators to the establishment of pharmacist-led CDTM exist and pharmacists can capitalize on these to create successful CDTM programs. Barriers are varied, and it may be difficult to systematically address individual barriers such as pharmacist autonomy and personal development. Barriers associated with institutional restrictions, the Georgia BOP, and lack of provider status can likely be removed or addressed by policy.